Drugs & Targets MD Anderson, Invectys, CTMC announce strategic collaboration for CAR T-cell therapy development June 17, 2022Vol.48 No.24
Guest Editorial ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer June 10, 2022Vol.48 No.23By George W. Sledge Jr.
In early results “unprecedented in rectal cancer,” 14/14 patients show clinical complete response to dostarlimab June 10, 2022Vol.48 No.23By Alice Tracey
Lowy calls for expanding NCI’s clinical impact, including: (1) the number of drug candidates, (2) the clinical trials system, and (3) access to cancer care June 10, 2022Vol.48 No.23By Alice Tracey
Clinical Roundup UNC study: Using telehealth to report symptoms improves well-being in advanced cancer June 10, 2022Vol.48 No.23
Clinical Roundup Parker Institute study: Biomarkers may predict better immunotherapy outcomes in mPDAC June 10, 2022Vol.48 No.23
Clinical Roundup N-803 immunotherapy may improve responses in BCG-unresponsive bladder cancer, advanced metastatic pancreatic cancer June 10, 2022Vol.48 No.23
